• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Image quiz: Whats going on with these dogs skin?

August 31, 2018
Brooke Britton, DVM, DACVIM (oncology)

Recurrent, multidrug-resistant skin infections that present with scaling and ulcerated, crusting lesions are signs of this condition.

Images courtesy of Dr. Brooke Britton.

These two dogs share the same condition, characterized by several weeks' to months' duration of multidrug-resistant, recurrent skin infections, with diffuse scaling and ulcerated, crusting lesions over the trunk and ventral abdomen, accompanied by intense pruritus. Which skin condition do you suspect looking at these images?

Cutaneous histiocytosis

Cutaneous lymphoma

Advertisement

Cutaneous mastocytosis

Hepatocutaneous syndrome

 

The answer is: B. Cutaneous lymphoma

The skin biopsy confirmed cutaneous lymphoma, which is a rare variant of lymphoma and is usually multifocal to generalized in the distribution of skin lesions. Secondary skin infections are common, and the diagnosis is often delayed as the condition mimics more common dermatologic conditions in the disease's beginning phases. Tumors can occur as nodules, plaques, ulcers, and erythemic or exfoliative dermatitis, and they are often accompanied by intense pruritus.

Epitheliotropic lymphoma (occasionally referred to as mycosis fungoides) is a cancer of T-lymphocyte origin and has three distinct stages: progressing from 1) scaling, alopecia and pruritus to 2) thickened, exudative, ulcerated lesions to 3) diffuse plaque-like or nodular lesions with severe ulceration. Nonepitheliotropic lymphoma spares the epidermis and primarily affects the middle and deep portions of the dermis and subcutis. Oral (mucocutaneous) involvement can also occur.

In the terminal phases of cutaneous lymphoma, progression in lymph nodes and internal organs as well as the bone marrow may result. Rarely, Sézary syndrome may occur, characterized by peripherally circulating, large, malignant T cells. Sézary syndrome carries a very poor to grave prognosis.

Cutaneous lymphoma is not considered a curable condition, with the exception of rare cases in which a single nodule is observed that may be treated surgically or with radiation therapy. The treatment of diffuse cutaneous lymphoma is often composed of a combination of steroids, chemotherapy (oral or injectable) and/or retinoids, which are biologic regulators of cell differentiation, proliferation, apoptosis and the immune response. A novel therapy, Tanovea-CA1 (VetDC), may also be used to treat this disease. The long-term prognosis for dogs with diffuse cutaneous lymphoma is typically poor, with most patients experiencing relapse or terminal progression of their disease within six to 12 months of diagnosis.

Brooke Britton, DVM, DACVIM (oncology), practices at BluePearl Veterinary Partners in New York, New York.

Related Content:

OncologyAssociatesDermatology
Can our Pride panel answer these LGBTQ+ trivia questions?
Can our Pride panel answer these LGBTQ+ trivia questions?
Creating inclusive spaces for the LGBTQ+ community in vet med
Creating inclusive spaces for the LGBTQ+ community in vet med
Happy Pride Month, Hill's launches Prescription Diet ONC Care, and more
Happy Pride Month, Hill's launches Prescription Diet ONC Care, and more

Advertisement

Latest News

Can our Pride panel answer these LGBTQ+ trivia questions?

Creating inclusive spaces for the LGBTQ+ community in vet med

Happy Pride Month, Hill's launches Prescription Diet ONC Care, and more

CityVet Celina opens in Prosper, Texas

View More Latest News
Advertisement